Holen Sie sich die Stockscreener-App
26.21
0.15%
0.04
Vorhandelsmarkt:
26.22
0.010
+0.04%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt PFE?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$26.17
Offen:
$26.29
24-Stunden-Volumen:
38.75M
Relative Volume:
1.06
Marktkapitalisierung:
$149.38B
Einnahmen:
$63.32B
Nettoeinkommen (Verlust:
$7.52B
KGV:
20.10
EPS:
1.3043
Netto-Cashflow:
$9.48B
1W Leistung:
+0.65%
1M Leistung:
+1.31%
6M Leistung:
+1.39%
1J Leistung:
+5.52%
1-Tages-Spanne:
$26.11
$26.49
1-Wochen-Bereich:
$25.47
$26.49
52-Wochen-Spanne:
$23.11
$28.75
Pfizer Inc Stock (PFE) Company Profile
Firmenname
Pfizer Inc
Sektor
Telefon
(212) 733-2323
Adresse
66 HUDSON BOULEVARD EAST, NEW YORK, NY
Compare PFE vs LLY, JNJ, ABBV, MRK, NVS
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PFE
Pfizer Inc
|
26.21 | 149.38B | 63.32B | 7.52B | 9.48B | 1.3043 |
LLY
Lilly Eli Co
|
1,133.00 | 1.01T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
240.87 | 579.83B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
227.73 | 402.35B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
119.05 | 294.03B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
153.07 | 292.07B | 54.66B | 13.58B | 16.05B | 7.0171 |
Pfizer Inc Stock (PFE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-02 | Hochstufung | Argus | Hold → Buy |
| 2026-02-25 | Eingeleitet | RBC Capital Mkts | Underperform |
| 2026-02-20 | Eingeleitet | Barclays | Underweight |
| 2026-02-12 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2026-01-07 | Fortgesetzt | UBS | Neutral |
| 2025-12-02 | Fortgesetzt | Citigroup | Neutral |
| 2025-11-13 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-04-22 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2024-12-10 | Fortgesetzt | BofA Securities | Neutral |
| 2024-11-15 | Eingeleitet | Wolfe Research | Underperform |
| 2024-10-25 | Fortgesetzt | Citigroup | Neutral |
| 2024-10-17 | Eingeleitet | Bernstein | Mkt Perform |
| 2024-08-07 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2024-03-22 | Herabstufung | Argus | Buy → Hold |
| 2024-02-23 | Eingeleitet | Guggenheim | Buy |
| 2024-01-04 | Herabstufung | TD Cowen | Outperform → Market Perform |
| 2023-10-20 | Fortgesetzt | UBS | Neutral |
| 2023-10-16 | Hochstufung | Jefferies | Hold → Buy |
| 2023-07-17 | Bestätigt | JP Morgan | Neutral |
| 2023-07-14 | Eingeleitet | HSBC Securities | Buy |
| 2023-06-29 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2023-05-11 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2023-03-06 | Eingeleitet | Jefferies | Hold |
| 2023-02-07 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2023-01-26 | Herabstufung | UBS | Buy → Neutral |
| 2023-01-17 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-01-04 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-12-13 | Hochstufung | Goldman | Neutral → Buy |
| 2022-11-18 | Eingeleitet | Credit Suisse | Outperform |
| 2022-05-23 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2022-04-06 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2022-01-05 | Hochstufung | BofA Securities | Neutral → Buy |
| 2022-01-03 | Bestätigt | Bernstein | Mkt Perform |
| 2021-12-20 | Bestätigt | Cowen | Outperform |
| 2021-12-17 | Eingeleitet | Goldman | Neutral |
| 2021-12-13 | Hochstufung | UBS | Neutral → Buy |
| 2021-12-09 | Eingeleitet | Wells Fargo | Overweight |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-07-27 | Fortgesetzt | Truist | Buy |
| 2021-05-06 | Herabstufung | Mizuho | Buy → Neutral |
| 2021-04-07 | Fortgesetzt | RBC Capital Mkts | Sector Perform |
| 2021-02-04 | Hochstufung | DZ Bank | Hold → Buy |
| 2020-12-16 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-11-19 | Fortgesetzt | Goldman | Neutral |
| 2020-11-10 | Fortgesetzt | Bernstein | Mkt Perform |
| 2020-10-12 | Herabstufung | Atlantic Equities | Overweight → Neutral |
| 2020-09-29 | Eingeleitet | Berenberg | Hold |
| 2020-06-16 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2020-02-27 | Eingeleitet | Barclays | Equal Weight |
| 2020-02-27 | Hochstufung | Standpoint Research | Hold → Buy |
| 2020-02-06 | Eingeleitet | Mizuho | Buy |
| 2020-01-07 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2019-10-17 | Fortgesetzt | BofA/Merrill | Neutral |
| 2019-07-30 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2019-07-30 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2019-06-04 | Fortgesetzt | Morgan Stanley | Overweight |
| 2019-02-20 | Fortgesetzt | Citigroup | Neutral |
| 2019-01-31 | Hochstufung | Argus | Hold → Buy |
| 2019-01-31 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2019-01-23 | Herabstufung | UBS | Buy → Neutral |
| 2018-12-11 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2018-11-01 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
Alle ansehen
Pfizer Inc Aktie (PFE) Neueste Nachrichten
Bio Usawa Appoints Dr. Aida Habtezion, Former Chief Medical Officer at Pfizer, to its Board of Directors - GlobeNewswire
SINOPHARM (01099.HK) Establishes Strategic Partnership with Pfizer, Inc. (PFE.US) - AASTOCKS.com
Pfizer Obesity Pipeline Gains Traction As Berobenatide Data Support Valuation - Yahoo Finance
Pfizer Holds Near $26, Dividend Draws Watch as Drug Prices Cloud Outlook - TechStock²
Comirnaty (Original/Omicron XBB.1.5): Updated mRNA COVID-19 vaccine in focus for US adults - AD HOC NEWS
Pfizer Inc. Stock (US7170811035): Analyst Views and Valuation Under the Microscope - AD HOC NEWS
Pfizer (PFE) Upgraded at RBC Capital. Here is Why - Insider Monkey
How Safe is Bristol Myers Squibb's Dividend? Here's My Honest Take. - The Motley Fool
Pfizer trades around $26 with dividend in focus, drug-price worries linger - TechStock²
Pfizer Pivots Hard: Obesity, Cancer Bets Tempt Investors - TipRanks
Insider trades: Microsoft, Tesla, Pfizer among notable names - Seeking Alpha
Pfizer (PFE): The Best Longevity Stock to Buy Now - Insider Monkey
Pfizer Draws Fresh Focus As Growth Strategy Evolves - Kalkine Media
Pfizer (PFE) Stock Valuation Check As Modest Recent Gains Meet Mixed Multi Year Returns - simplywall.st
Dividend HistoryPfizer (PFE) - Zacks Investment Research
Pfizer Draws Fresh Attention As Pipeline Activity Accelerates - Kalkine Media
Pfizer's New Weight-Loss Data Just Gave Eli Lilly and Novo Nordisk Investors Something to Worry About - Yahoo Finance
Pfizer Still Trades Over $26 as RBC Lift Balances Out Drug-Pricing Concerns - TechStock²
ORIC gains as Stifel resumes at Buy on upcoming Pfizer readout - Seeking Alpha
SpaceX IPO: Value Investors Warn You're Buying A StoryPfizer (NYSE:PFE), SpaceX (NASDAQ:SPCX) - Benzinga
Pfizer Oncology Data Underscore Survival Gains And Valuation Debate - Yahoo Finance
US legislation targets China pharma IP licensing following multi-billion Pfizer, BMS deals - IAM Patent
Pfizer Inc. $PFE Shares Bought by Xponance LLC - MarketBeat
Pfizer Inc. $PFE Stake Lowered by Swiss National Bank - MarketBeat
Pfizer Inc. $PFE Shares Sold by Te Ahumairangi Investment Management Ltd - MarketBeat
Kovack Advisors Inc. Buys 64,044 Shares of Pfizer Inc. $PFE - MarketBeat
ICICI Prudential Asset Management Co Ltd Has $4.11 Million Stock Position in Pfizer Inc. $PFE - MarketBeat
Pfizer Inc. $PFE Shares Purchased by IFM Investors Pty Ltd - MarketBeat
Alps Advisors Inc. Sells 57,526 Shares of Pfizer Inc. $PFE - MarketBeat
First Financial Bankshares Inc Sells 54,776 Shares of Pfizer Inc. $PFE - MarketBeat
Pfizer Inc. $PFE Shares Purchased by Aviva PLC - MarketBeat
Pfizer Inc. (NYSE:PFE) Receives Consensus Rating of "Hold" from Analysts - MarketBeat
Does New GLP‑1 Data And HYMPAVZI Expansion Reshape The Bull Case For Pfizer (PFE)? - simplywall.st
Pfizer (PFE) Outpaces Stock Market Gains: What You Should Know - Yahoo Finance
Pfizer (NYSE:PFE) Shares Up 2.2%Here's What Happened - MarketBeat
Pfizer Inc. stock outperforms competitors on strong trading day - MarketWatch
PFE Stock Quote Price and Forecast - CNN
This $25 Billion Acquisition Just Unlocked a New Era of Growth for Pfizer — and Why It’s a Flawless Safe-Haven for Retirees - Yahoo Finance
A Sizzling 6.7% Dividend Yield? 1 Under-the-Radar Reason I Am Holding Off on Pfizer Stock at $25 - Yahoo Finance
Pfizer’s New Phase 1 PF-07799544 Study Adds Quiet Depth to Its R&D Pipeline - TipRanks
Why Pfizer Stock Popped Today - The Globe and Mail
Pfizer Shares Edge Higher on RBC Upgrade, German Pricing Risk in Focus - TechStock²
Lexicon Pharmaceuticals vs Pfizer: Comparing a Small Biotech with a Global DrugmakerNews and Statistics - IndexBox
Pfizer shares climb 3.2% as investors digest expanded U.S. label for HYMPAVZI - Quiver Quantitative
Lexicon Pharmaceuticals vs. Pfizer: Which Drugmaker Stock Is a Better Buy in 2026? - Yahoo Finance
Pfizer Inc. $PFE Stock Position Lowered by Townsquare Capital LLC - MarketBeat
Insider Sell: Jennifer Damico Sells 2,000 Shares of Pfizer Inc (PFE) - GuruFocus
Veteran Analyst Revamps Pfizer Stock Price Target for Rest of 2026 - TradingView
Roche and Pfizer race to lead obesity and diabetes drug market with promising new treatments. - Pluang
Roche Vs. Pfizer: Obesity Week Presentations Deep DiveWhat Investors Must Know (RHHBY) - Seeking Alpha
Pfizer Steps Up in Obesity Race With New Mid-Stage SOLIS-1 Trial - TipRanks
Finanzdaten der Pfizer Inc-Aktie (PFE)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.22%
0.32%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):